Perioperative Perfusion of Allografts with Anti-Human T-lymphocyte Globulin Does Not Improve Outcome Post Liver Transplantation—A Randomized Placebo-Controlled Trial
Authors:
- Paul Viktor RitschlPRPaul Viktor Ritschl
- Julia GüntherJGJulia Günther
- Lena HofhanselLHLena Hofhansel
- Stefanie ErnstSEStefanie Ernst
- Susanne EbnerSESusanne Ebner
- Arne SattlerASArne Sattler
- Sascha WeißSWSascha Weiß
- Annemarie WeissenbacherAWAnnemarie Weissenbacher
- Rupert OberhuberRORupert Oberhuber
- Benno CardiniBCBenno Cardini
- Robert ÖllingerRobert Öllinger
- Matthias BieblMatthias Biebl
Open Access
- 25 June 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2816
Abstract
Due to the lack of suitable organs transplant surgeons have to accept unfavorable extended criteria donor (ECD) organs. Recently, we demonstrated that the perfusion of kidney organs with anti-human T-lymphocyte globulin (ATLG) prior to transplantation ameliorates ischemia-reperfusion injury (IRI). Here, we report on the results of perioperative ATLG perfusion in a randomized, single-blinded, placebo-controlled, feasibility trial (RCT) involving 30 liver recipients (LTx). Organs were randomly assigned for perfusion with ATLG/Grafalon® (AP) (n = 16) or saline only (control perfusion = CP) (n = 14) prior to implantation. The primary endpoint was defined as graft function reflected by aspartate transaminase (AST) values at day 7 post-transplantation (post-tx). With respect to the primary endpoint, no significant differences in AST levels were shown in the intervention group at day 7 (AP: 53.0 ± 21.3 mg/dL, CP: 59.7 ± 59.2 mg/dL, p = 0.686). Similarly, exploratory analysis of secondary clinical outcomes (e.g., patient survival) and treatment-specific adverse events revealed no differences between the study groups. Among liver transplant recipients, pre-operative organ perfusion with ATLG did not improve short-term outcomes, compared to those who received placebo perfusion. However, ATLG perfusion of liver grafts was proven to be a safe procedure without the occurrence of relevant adverse events.Keywords
Funding Information
- California Department of Fish and Game (DFG-PR578/2-3/4)
This publication has 49 references indexed in Scilit:
- Ischaemia–reperfusion injury in liver transplantation—from bench to bedsideNature Reviews Gastroenterology & Hepatology, 2012
- Induction of bona fide regulatory T cells after liver transplantation - the potential influence of polyclonal antithymocyte globulinTransplant International, 2011
- Cellular pathophysiology of ischemic acute kidney injuryJournal of Clinical Investigation, 2011
- Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantationTransplant International, 2011
- Lymphocytes and ischemia-reperfusion injuryTransplantation Reviews, 2009
- Methylprednisolone Therapy in Deceased Donors Reduces Inflammation in the Donor Liver and Improves Outcome After Liver TransplantationAnnals of Surgery, 2008
- Mechanisms of action of antithymocyte globulin: T-cell depletion and beyondLeukemia, 2007
- A Novel Mechanism of Action for Anti-Thymocyte GlobulinJournal of the American Society of Nephrology, 2006
- Influence of polyclonal anti-thymocyte globulins upon ischemia–reperfusion injury in a non-human primate modelTransplant Immunology, 2006
- Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins1Transplantation, 2003